Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Researchers found that patients who took statins alongside apalutamide and standard hormone therapy had higher three-year ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

The American Cancer Society tracks survival rates for 22 types of localized cancer, including the most common in the US: prostate (100%), skin (99.6% five-year survival rate), breast (99.3%), lung (65 ...